Every Form 4 that Vivos Therapeutics, Inc. (VVOS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow VVOS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VVOS filings page.
Vivos Therapeutics, Inc. (VVOS) reported that director Leonard J. Sokolow received a grant of 12,000 stock options on September 14, 2026 at an exercise price of $0.18 per share, expiring September 14, 2036. One-half vested immediately, with one-fourth vesting on September 30, 2026 and one-fourth on December 31, 2026, bringing his directly held options to 17,600.
Vivos Therapeutics, Inc. (VVOS) reported that director Gregg C. Johnson received a grant of 12,000 stock options on September 14, 2026, each with an exercise price of $0.18 per share and a 10-year term. One-half of the options vested immediately, one-fourth will vest on September 30, 2026, and one-fourth will vest on December 31, 2026. After this grant, he holds 12,000 options directly and 3,997 shares of common stock indirectly through an affiliated limited partnership.
Vivos Therapeutics, Inc. (symbol: VVOS) is the issuer of record for a Form 4 filing submitted to the SEC.
Vivos Therapeutics, Inc. (VVOS) reported that Principal Accounting Officer Bradford K. Amman received equity awards on July 31, 2026. He was granted 150,000 stock options with an exercise price of $0.41 per share, expiring July 31, 2036, and a separate grant of 250,000 shares of common stock at $0.41 per share. Following these grants, he holds 326,533 stock options and 250,080 shares of common stock directly. The option grant was made under the company’s 2024 Omnibus Equity Incentive Plan and is scheduled to vest at a stated rate of 25,000 shares per month from November 1, 2026 through April 1, 2026.
Vivos Therapeutics, Inc. large shareholder Michael C. Skaff, through V-Co Investors 4 LLC, recorded purchases totaling 5,498,660 derivative securities tied to common stock on June 30, 2026. The entity acquired 2,749,330 Common Stock Purchase Warrants and blocks of Series A Convertible Preferred Stock (1,890,164 and 859,166 shares) at $0.582 per unit.
The warrants are exercisable for common shares at $0.456 per share until June 30, 2031. The Series A Convertible Preferred Stock is convertible into common stock at any time, subject to a beneficial ownership limitation and has no expiration date. A footnote states that V-Co Investors 4 LLC converted a $1,000,000 bridge promissory note into Series A Convertible Preferred Stock, and Skaff and SP Manager LLC disclaim beneficial ownership beyond their pecuniary interest.
Vivos Therapeutics, Inc. disclosed that V-Co Investors 3 LLC, a ten percent owner associated with Michael C. Skaff, made a series of open-market purchases on March 31, 2026. The entity bought 1,353,625 shares of common stock at $1.34 per share, plus pre-funded and Series A and B common stock warrants at the same price, covering a total of 5,350,746 securities including underlying common shares. A bridge promissory note of $1,400,000 was also converted into common stock based on $1.09 per share plus $0.25 per share under Nasdaq minimum price rules. The Pre-Funded Warrant has a term ending upon complete exercise, while the Series A and Series B warrants have exercise prices of $1.09 and expire on March 31, 2028 and March 31, 2031, respectively. Skaff and SP Manager LLC disclaim beneficial ownership except to the extent of their pecuniary interest.